Clinical trials: Behavioural Disorder
Pulmonary Fibrosis, Anxiety
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.
- Trial name
- COMPANION (NCT05330312)
- Testing
- Digital cognitive behavioral therapy
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- Vicore Pharma AB
Attention Deficit Disorder With Hyperactivity
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
- Trial name
- NCT04113551
- Testing
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO)
- Where
- United States
- Volunteers
- 17,418 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT02699086
- Testing
- PDC-1421 Capsule
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- BioLite, Inc.
Hearing Loss
Physiological, Behavioural and Subjective Measures of Listening Effort
Participants will perform two different listening tasks: (1) listening to, and repeating back, sentence lists presented in noise, and (2) listening to short radio excerpts and answering subsequent comprehension questions.
- Trial name
- NCT03761927
- Testing
- Hearing Aid without NR enabled, Hearing Aid with NR(1), Hearing Aid with NR(2)
- Where
- Switzerland
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Sonova AG
Attention Deficit Hyperactivity Disorder
A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl as compared with placebo and standard immediate-release Ritalin® (taken three time per day) for the treatment of Attention Deficit…
- Trial name
- NCT00269802
- Testing
- OROS methylphenidate HCl, Ritalin
- Sponsor
- Alza Corporation, DE, USA
Attention Deficit Hyperactivity Disorder
Training Attentional Awareness and Control in ADHD
The purpose of this study is to evaluate the effects of different types of cognitive training on attention in adults with Attention Deficit Hyperactivity Disorder (ADHD) using mobile software on personal mobile devices.
- Trial name
- SAC-I (NCT02489279)
- Testing
- Sustained Attention Control (SAC) Method, Scrabble
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Think Now Incorporated
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD)…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT00249158
- Testing
- Risperidone
- Volunteers
- 344 people
- Sponsor
- Janssen-Cilag Pty Ltd
Attention Deficit Hyperactivity Disorder
Online Neuroplasticity Training for Remediation of ADHD in Adolescent Children (ONTRAC)
This project shall rigorously evaluate the effectiveness of a novel, neuroplasticity-based internet-deliverable cognitive training program, which specifically targets the treatment of core cognitive dysfunctions observed in…
- Trial name
- NCT01772485
- Testing
- Cognitive Training, Active Control
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD
Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA® in pediatric subjects diagnosed with ADHD.
- Trial name
- NCT00444574
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 282 people
- Sponsor
- Noven Therapeutics
Attention Deficit/Hyperactivity Disorder
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
To evaluate long-term safety exposure
- Trial name
- NCT05279313
- Testing
- Centanafadine Hydrochloride
- Where
- 86 sites in United States, Canada and 1 more
- Volunteers
- 680 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.
- Trial name
- NCT07169162
- Testing
- ADZENYS XR-ODT
- Where
- United States
- Sponsor
- Aytu BioPharma, Inc.
Attention Deficit Hyperactivity Disorder
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity…
- Trial name
- EMD (NCT01127646)
- Testing
- Atomoxetine, Osmotic-release oral system methylphenidate
- Where
- 14 sites in Netherlands, Spain and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
ADHD
An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- A-GAMES (NCT05805176)
- Testing
- ADHD Therapy
- Where
- 5 sites in United States
- Volunteers
- 194 people
- Sponsor
- Lumos Labs, Inc.
Attention Deficit Hyperactivity Disorder
A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00880217
- Testing
- Atomoxetine 80 mg/d, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d
- Where
- 35 sites in United States
- Volunteers
- 430 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
CX717 in the Treatment of Adult ADHD
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder
- Trial name
- NCT03375021
- Testing
- CX717 200 mg, CX717 800 mg
- Volunteers
- 68 people
- Sponsor
- RespireRx
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
The purpose of the study is to investigate the clinical benefit of switching children with ADHD from immediate-release methylphenidate (IR-MPH) to OROS-methylphenidate under the correct dosage conversion scheme.
- Trial name
- NCT00518232
- Testing
- OROS-methylphenidate
- Volunteers
- 520 people
- Sponsor
- Johnson & Johnson Taiwan Ltd